Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy

Table 2 Demographic and clinical characteristics between patients with objective response and patients without objective response n (%)

Characteristics	Objective response		P value	P value1
	No	Yes
Age, yr (mean ± SD)	48.2 ± 10.9	52.1 ± 9.0	0.0472	0.066
Gender
Male	44 (62.0)	27 (38.0)	0.4023	0.492
Female	34 (69.4)	15 (30.6)
KPS
≥ 80%	64 (66.7)	32 (33.3)	0.4443	0.42
< 80%	14 (58.3)	10 (41.7)
Primary tumor
Right-sided	22 (66.7)	11 (33.3)	0.8143	0.885
Left-sided	56 (64.4)	31 (35.6)
Histology
Glandular	55 (61.8)	34 (38.2)	0.2133	0.407
Other	23 (74.2)	8 (25.8)
First-line chemotherapy
FOLFIRI	71 (65.1)	38 (34.9)	0.8824	0.832
mXELIRI	4 (57.1)	3 (42.9)
Irinotecan	3 (75.0)	1 (25.0)

¹P-values were adjusted for age, sex, KPS, primary tumor site, histology and treatment regimen in logistic regression models;

²P-value was calculated using two-sided t tests;

³P-values were calculated using two-sided χ² tests;

⁴P-value was calculated using Fisher’ exact tests. KPS: Karnofsky performance status.